BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Anand Rathi maintains buy on Suven Life Sciences
Expect ramp-up in revenue and profit led by the commencement of commercial supplies for innovative molecules. Cut revenue estimates for FY16, FY17 and FY18 by 9.9, 8.9 and 9.1 per cent due to lower-than expected performance in the first nine months of FY16.